Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
Filter the results
The Democratic Republic of Congo will introduce a second Ebola vaccine next month to counter the outbreak of the disease in the country.
Four companies have agreed with the UK government to deliver medicines to the country after Brexit, signing contracts worth £86.6 million.
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera always puts patients first, providing high-quality solutions that have a demonstrable impact on patients’ health, including off-the-shelf innovative systems, customized design development and GMP contract manufacturing.
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
The Secretary of State for Health and Social Care is supporting the continuity of medical supplies if the UK is to leave the EU without a deal.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
Custom manufacturing of specialty chemicals and APIs.
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.